KSC · 207940.KS
Samsung Biologics Co.,Ltd.
₩1,487,000+₩121,000 (+8.86%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
Loading market information…
KOE · 226950.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
OliX Pharmaceuticals,Inc’s quoted price sits in the lower half of its reported 52-week range, 56.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow OliX Pharmaceuticals,Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OliX Pharmaceuticals, Inc. is a biotechnology firm in the clinical development phase, specializing in the creation of RNA interference (RNAi) treatments. Its primary focus lies in developing therapies for various conditions affecting the skin (dermal), eyes (ophthalmic), and lungs (pulmonary). The company maintains a robust pipeline of experimental medicines, including: For dermatological applications: OLX101 (targeting skin scars), OLX102 (for skin whitening), OLX103 (an atopic dermatitis candidate), OLX104 (addressing hair loss), OLX105 (an anti-wrinkle product), and OLX106 (for diabetic foot ulcers). For ophthalmic disorders: OLX301 (for age-related macular degeneration retinal fibrosis) and OLX304 (for retinitis pigmentosa). For respiratory diseases: OLX201 (lung fibrosis), OLX202 (asthma), and OLX203 (influenza). Other significant programs encompass: OLX401 (neuropathic pain), OLX701 (liver fibrosis), and a distinct OLX701 designated for cancer immunotherapy. Furthermore, OliX Pharmaceuticals has forged strategic partnerships, including a collaborative agreement with Théa to advance SiRNA therapeutics for eye-related diseases, and a research alliance with PCI Biotech Holding ASA. Established in 2010, the company's operations are based in Suwon, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩1,487,000+₩121,000 (+8.86%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
₩191,600+₩2,300 (+1.22%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
₩211,500-₩8,500 (-3.86%)
Alteogen Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.68% below the high.
₩309,500+₩2,500 (+0.81%)
Samsung Epis Holdings’s quoted price sits in the lower half of its reported 52-week range, 59.96% below the high.
₩77,700-₩100 (-0.13%)
SK Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.08% below the high.
₩40,000+₩300 (+0.76%)
HLB Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.2% below the high.
₩415,000+₩26,500 (+6.82%)
Hanmi Pharm. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.86% below the high.
₩75,100+₩400 (+0.54%)
Yuhan Corporation’s quoted price sits in the lower half of its reported 52-week range, 41.87% below the high.
